Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?

Jason Liebowitz, MD, FACR  |  November 9, 2020

ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…

Filed under:ACR ConvergenceDrug UpdatesMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RA

Low-Dose Methotrexate Can Cause Adverse Effects

Will Boggs, MD  |  February 19, 2020

NEW YORK (Reuters Health)—Low-dose methotrexate can be associated with gastrointestinal, pulmonary, infectious, hematologic and other adverse effects, according to an analysis of the Cardiovascular Inflammation Reduction Trial (CIRT). “Methotrexate is not a benign drug, even at dosages used for rheumatic diseases,” Daniel H. Solomon, MD, MPH of Brigham and Women’s Hospital, Boston, tells Reuters Health…

Filed under:Drug Updates Tagged with:adverse eventsMethotrexate

Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout

Michele B. Kaufman, PharmD, BCGP  |  December 11, 2019

Patients with uncontrolled gout may benefit from a combination of pegloticase and methotrexate therapy, according to a small, retrospective study…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis

Case Report: RA Patient Suffers Methotrexate-Induced Cutaneous Lesions

Nitasha Kumar, MD  |  August 16, 2019

Methotrexate (MTX) remains the predominant medication used by rheumatologists to treat rheumatoid arthritis (RA). Doses of 7.5–25 mg per week with daily folic acid are generally prescribed. Despite its common use, MTX must be prescribed cautiously given the potential adverse effects when taken incorrectly or without folic acid supplementation. Cases of MTX-induced cutaneous ulceration have…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Methotrexatetoxicity

RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy

Michele B. Kaufman, PharmD, BCGP  |  July 29, 2019

RA patients who achieve low disease activity on tofacitinib and methotrexate combination therapy can safely cease methotrexate use, according to recent research…

Filed under:Drug UpdatesEULAR/OtherMeeting Reports Tagged with:combination therapyEULARMethotrexatemonotherapyRheumatoid Arthritis (RA)Tofacitinib

Upadacitinib + Methotrexate & Other csDMARDs in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  July 12, 2019

A post-hoc analysis showed upadacitinib is safe and effective for treating RA patients when used with methotrexate or non-methotrexate csDMARDs…

Filed under:Drug UpdatesEULAR/OtherMeeting Reports Tagged with:combination therapyEULARMethotrexateRheumatoid Arthritis (RA)upadacitinib

Tofacitinib + Methotrexate: 2-Year Clinical, Radiographic & Safety Outcomes

Michele B. Kaufman, PharmD, BCGP  |  June 4, 2019

In a 24-month clinical trial, tofacitinib proved safe and effective in combination with methotrexate in adult patients with RA…

Filed under:Drug Updates Tagged with:MethotrexateRheumatoid Arthritis (RA)Tofacitinib

Li Wa / shutterstock.com

7 Insights into Methotrexate Administration, Drug Resistance & Toxicity

Thomas R. Collins  |  February 18, 2019

CHICAGO—Once methotrexate enters a cell through the reduced folate carrier (RFC), which thinks it is picking up folate, the drug is polyglutamated. It is this polyglutamate methotrexate that provides the actual clinical effect. These methotrexate polyglutamate “species” are added and lost over time, but it’s a slow process. What difference does it make whether a…

Filed under:Drug UpdatesMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingMethotrexate

Adalimumab + Methotrexate Effective for Uveitis in JIA

Lara C. Pullen, PhD  |  October 2, 2017

Research has found that taking adalimumab plus methotrexate is effective for patients with juvenile idiopathic arthritis-associated uveitis. However, these patients may also experience an increased incidence of adverse and serious adverse events compared with those taking only methotrexate…

Filed under:ConditionsOther Rheumatic ConditionsPediatric Conditions Tagged with:adalimumabJIAJuvenile Arthritis (JIA)MethotrexatePediatricPediatric RheumatologyUveitis

Effectiveness of Tofacitinib with Methotrexate, Adalimumab Therapy Evaluated in Patients with RA

Thomas R. Collins  |  September 19, 2017

MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of Rheumatology (EULAR). The findings came in a one-year…

Filed under:ConditionsDrug UpdatesResearch RheumRheumatoid Arthritis Tagged with:adalimumabAnnual European Congress of RheumatologyClinicalDisease-modifying antirheumatic drugs (DMARDs)effectivenessEULARMedicationMethotrexateORAL Strategyoutcomepatient careRAResearchRheumatoid arthritisrheumatologytherapyTofacitinib

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 106
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences